Skip to main content
OpenTrials

Clinical trial condition

Multiple Sclerosis, Relapsing-Remitting

Explore clinical trials studying Multiple Sclerosis, Relapsing-Remitting. Study availability and eligibility vary by location and protocol.

455 public trials 46 recruiting studies
Refine in advanced search Browse all conditions

Multiple Sclerosis, Relapsing-Remitting trial results

Completed

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

NCT02637856

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • North Central Neurology Associates Cullman, Alabama, United States
  • Phoenix Neurological Associates Ltd Phoenix, Arizona, United States
  • Barrow Neurological Institute Phoenix, Arizona, United States
  • Territory Neurology and Research Institute Tucson, Arizona, United States
View all 82 locations
View Trial Details
Completed

A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes

NCT01930708

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Innsbruck, Austria
  • Research Site Klagenfurt, Austria
  • Research Site Linz, Austria
  • Research Site Salzburg, Austria
View all 90 locations
View Trial Details
Completed

Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

NCT00203021

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Teva Investigational Site 009 Los Angeles, California, United States
  • Teva Investigational Site 004 Los Angeles, California, United States
  • Teva Investigational Site 008 New Haven, Connecticut, United States
  • Teva Investigational Site 005 Baltimore, Maryland, United States
View Trial Details
Completed

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

NCT00879658

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Brain Diseases, +16 more
Locations
  • Novartis Investigative Site Cullman, Alabama, United States
  • Novartis Investigative Site San Francisco, California, United States
  • Novartis Investigative Site Centennial, Colorado, United States
  • Novartis Investigative Site Miami, Florida, United States
View all 72 locations
View Trial Details

Related conditions